

Supplementary Table 1: Demographical and clinical characteristics of the study subjects by BIC/FTC/TAF and 3TC + EFV + TDF groups.

Characteristic	Total N = 870	BIC/FTC/TAF (N = 510)	3TC + EFV + TDF (N = 360)	χ^2/t	P-value
Age	32.8 (27.0, 41.2)	32.0 (27.3, 38.8)	34.0 (26.0, 46.0)	1.843	0.066*
18–27 years	214 (24.6)	119 (23.3)	95 (26.4)	26.519	<0.001 [†]
27–32 years	191 (22.0)	134 (26.3)	58 (16.1)		
32–41 years	237 (27.2)	151 (29.6)	86 (23.9)		
≥41 years	227 (26.1)	106 (20.8)	121 (33.6)		
Nationality				0.330	0.566 [†]
Han	803 (92.3)	468 (91.8)	335 (93.1)		
Others	67 (7.7)	42 (8.2)	25 (6.9)		
Education				121.160	<0.001 [†]
High school and below	325 (37.4)	116 (22.7)	209 (58.1)		
Bachelor’s degree or college	473 (54.4)	330 (64.7)	143 (39.7)		

Master and above	71 (8.2)	63 (12.4)	8 (2.2)		
BMI (kg/m ²)	22.5 (20.3, 25.0)	22.6 (20.6, 25.2)	22.4 (20.2, 24.7)	0.403	0.687*
Lean	64 (7.4)	32 (6.3)	32 (8.9)	3.094	0.377 [†]
Normal	495 (56.9)	297 (58.2)	198 (55)		
Overweight	222 (25.5)	128 (25.1)	94 (26.1)		
Obesity	84 (9.7)	53 (10.4)	31 (8.6)		
Marital status				23.274	<0.001 [†]
Unmarried	551 (63.3)	355 (69.6)	196 (54.4)		
Married	252 (29)	117 (22.9)	135 (37.5)		
Divorced or widowed	66 (7.6)	37 (7.3)	29 (8.1)		
Baseline CD4 cell count (cells/μL)	322 (206, 452.8)	311.3 (183.9, 443.8)	350 (233.9, 463.6)	2.285	0.023*
<200	213 (24.5)	143 (28.0)	70 (19.4)	7.973	0.005 [†]
≥200	657 (75.5)	367 (72.0)	290 (80.6)		
Baseline CD8 cell count (cells/μL)				0.319	0.853 [†]
<500	141 (16.2)	82 (16.1)	59 (16.4)		

500–999	352 (40.5)	203 (39.8)	149 (41.4)		
≥1000	377 (43.3)	225 (44.1)	152 (42.2)		
Baseline CD4/CD8 ratio				0.119	0.730 [†]
<1.0	840 (96.6)	491 (96.3)	349 (96.9)		
≥1.0	30 (3.4)	19 (3.7)	11 (3.1)		
Baseline HIV RNA (copies/mL)	22,347 (5775, 77,567)	25,876.5 (6884.5, 96,913.3)	18,815 (5083.8, 54,665.5)	3.514	<0.001 [*]
<100,000	690 (79.3)	386 (75.7)	304 (84.4)	9.339	0.002 [†]
≥100,000	180 (20.7)	124 (24.3)	56 (15.6)		
Diabetes history				3.988	0.263 [†]
Yes	16 (1.8)	12 (2.4)	4 (1.1)		
No	842 (96.8)	488 (95.7)	354 (98.3)		
Cigarette smoking				8.578	0.003 [†]
Yes	302 (34.7)	155 (30.4)	147 (40.8)		
No	559 (64.3)	346 (67.8)	213 (59.2)		
Alcohol drinking				0.652	0.419 [†]

Yes	261 (30)	146 (28.6)	115 (31.9)
No	600 (69)	355 (69.6)	245 (68.1)

Data are presented as median (IQR), n (%).

3TC + EFV + TDF: Lamivudine, efavirenz, and tenofovir disoproxil fumarate; BIC/FTC/TAF: Bictegravir, emtricitabine, and tenofovir alafenamide; BMI: Body Mass Index; HIV: Human immunodeficiency virus; IQR: Interquartile range.

**P*-values were from the Wilcoxon rank-sum test to compare the two groups.

†*P*-values were from the chi-squared test to compare the two groups.

Supplementary Table 2: Blood dyslipidemia (LDL-C increasing) and their univariate analysis among naive treated male adult HIV/AIDS patients.

Variables	LDL-C increasing		Follow-up time/person weeks	Incidence/100 person weeks	HR (95% CI)	<i>P</i> -value
	Yes (%)	No (%)				
Total	19 (2.2)	851 (97.8)	26,906.92	0.07		
Nationality						
Han	16 (84.2)	787 (92.5)	24,740.34	0.06	1.00	

Others	3 (15.8)	64 (7.5)	2166.58	0.14	0.86 (0.69–1.07)	0.170
Age (years)						
18–27	1 (5.3)	213 (25)	6668.05	0.01	1.00	
27–32	4 (21.1)	188 (22.1)	5948.39	0.07	0.97 (0.83–1.14)	0.735
32–41	11 (57.9)	226 (26.6)	7600.92	0.14	0.87 (0.74–1.01)	0.083
≥41	3 (15.8)	224 (26.3)	6698.56	0.04	1.01 (0.86–1.19)	0.861
Education						
High school and below	5 (26.3)	320 (37.6)	10,059.10	0.05	1.00	
Bachelor's degree or college	11 (57.9)	462 (54.3)	14,698.78	0.07	1.01 (0.89–1.14)	0.860
Master and above	3 (15.8)	68 (8)	2117.75	0.14	1.10 (0.86–1.41)	0.447
BMI (kg/m²)						
Lean	0 (0)	64 (7.5)	2010.33	0	1.00	
Normal	12 (63.2)	483 (56.8)	14,876.40	0.08	1.01 (0.82–1.25)	0.911
Overweight	5 (26.3)	217 (25.5)	7135.20	0.07	0.90 (0.72–1.13)	0.357

Obesity	2 (10.5)	82 (9.6)	2644.99	0.08	0.93 (0.71–1.23)	0.624
Marital status						
Unmarried	11 (57.9)	540 (63.5)	16,888.68	0.07	1.00	
Married	6 (31.6)	246 (28.9)	7770.02	0.08	0.95 (0.83–1.08)	0.448
Divorced or widowed	2 (10.5)	64 (7.5)	2214.93	0.09	0.80 (0.63–1.01)	0.060
Diabetes history						
Yes	0 (0)	16 (1.9)	535.89	0	1.00	
No	18 (94.7)	824 (96.8)	26,012.02	0.07	0.97 (0.59–1.59)	0.894
Smoke						
Yes	8 (42.1)	294 (34.5)	9693.70	0.08	1.00	
No	10 (52.6)	549 (64.5)	16,976.07	0.06	1.14 (0.99–1.31)	0.069
Alcohol drinking						
Yes	6 (31.6)	255 (30)	8212.34	0.07	1.00	
No	12 (63.2)	588 (69.1)	18,457.43	0.07	1.02 (0.90–1.16)	0.757
Baseline CD4 cell count (cells/ μ L)						

<200	3 (15.8)	210 (24.7)	5965.00	0.05	1.00	
≥200	16 (84.2)	641 (75.3)	20,941.92	0.08	1.28 (0.37–4.31)	0.696
Baseline CD8 cell count (cells/μL)						
<500	0 (0)	141 (16.6)	3537.66	0	1.00	
500–999	10 (52.6)	342 (40.2)	10,821.83	0.09	0.69 (0.57–0.84)	<0.001
≥1000	9 (47.4)	368 (43.2)	12,547.43	0.07	0.64 (0.54–0.77)	<0.001
Baseline CD4/CD8						
<1.0	19 (100.0)	821 (96.5)	26,089.93	0.07	1.00	
≥1.0	0 (0)	30 (3.5)	816.99	0	1.17 (0.83–1.63)	0.369
Baseline HIV RNA (copies/mL)						
<100,000	16 (84.2)	674 (79.2)	22,058.20	0.07	1.00	
≥100,000	3 (15.8)	177 (20.8)	4848.72	0.06	1.26 (1.07–1.48)	0.005
Regime						
BIC/FTC/TAF	14 (73.7)	496 (58.3)	15,220.92	0.09	1.00	

3TC + EFV + TDF	5 (26.3)	355 (41.7)	11,686.00	0.04	0.80 (0.71–1.30)	0.890
-----------------	----------	------------	-----------	------	------------------	-------

3TC + EFV + TDF: Lamivudine, efavirenz, and tenofovir disoproxil fumarate; BIC/FTC/TAF: Bictegravir, emtricitabine, and tenofovir alafenamide; BMI: Body Mass Index; HIV/AIDS: Human immunodeficiency virus/acquired immunodeficiency syndrome; HR: Hazard Ratio; LDL-C: Low-density lipoprotein cholesterol.